Week In Review: Tianjin CanSino Closes $65 Million Round For Vaccine Portfolio
April 22, 2017 at 16:40 PM EDT
Tianjin CanSino Biologics, a vaccine developer, raised $65 Million in its latest funding round. Currently, CanSino is testing four products in Phase I to III clinical trials, conducted in North America, Africa and China respectively.
